Clinical Trial Update: An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations [Phase 1, Phase 2]

View source ↗

Summary

This update indicates that the Phase 1/Phase 2 trial of ASP8273 in EGFR-mutant non-small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ASP8273

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: TERMINATED